{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-076837","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.416497+00:00","generated_at":"2026-05-17T14:32:14.180670+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Theravance Biopharma Q2 net income $54.8M driven by $225M TRELEGY royalty sale; YUPELRI sales +22%","bullets":["YUPELRI net sales $66.3M (Viatris-recorded) up 22% YoY; Q2 implied 35% share $23.2M.","Completed sale of TRELEGY royalty interest to GSK for $225M; net gain of $75.1M.","Pivotal Phase 3 CYPRESS study enrollment nearing completion; top-line data ~6 months later.","Cash $339M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.","Non-GAAP net loss from operations improved to $4.2M from $6.3M YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-076837","json":"https://secwatch.observer/filing/0001104659-25-076837.json","markdown":"https://secwatch.observer/filing/0001104659-25-076837.md","text":"https://secwatch.observer/filing/0001104659-25-076837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925076837/0001104659-25-076837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925076837/tm2523183d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:32:14.180670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}